FDA Prescription Drug User Fee Program Will Get OIG Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to user fees, upcoming FDA reviews will also focus on oversight of post-marketing requirements and information exchange in the drug supply chain.
You may also be interested in...
PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says
FDA tells industry that proposal on trials also can’t use SPA-like process.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.